Barclays
CDAK

Barclays’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Barclays’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-140
Closed – – 5270
2022
Q2 		$0 Sell
140
-2,445
-95% -$8.59K ﹤0.01% 5407
2022
Q1 		$17K Buy
+2,585
New +$16.2K ﹤0.01% 4494

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays's CDAK Position: Q3 2022 in Review

Barclays sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q3 2022, closing a stake of 140 shares.

Barclays first reported a position in CDAK in Q1 2022 and held it in 2 quarters. The position peaked at $17K in Q1 2022. 48 funds tracked by Wall St. Rank hold CDAK as of Q3 2022.

  • Barclays reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 140 Codiak BioSciences, Inc. Common Stock shares in Q3 2022.
  • Barclays first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Barclays's Codiak BioSciences, Inc. Common Stock position peaked at $17K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.